Remove Pharmaceutical Companies Remove RNA Remove Small Molecule
article thumbnail

From Impossible to Inevitable: Transforming Undruggable Targets

DrugBank

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Beyond Proteins: DNA and RNA Frontier The story doesn’t end with proteins.

article thumbnail

Metabolism of 2022 FDA approved small molecule drugs PART 1

Metabolite Tales Blog

Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t come as much surprise to learn that of the 17 small molecules* approved by the FDA in 2022, CYP3A4 was the major player in drug metabolism. References Iversen et al., Front Pharmacol.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. There, I supported AI-enabled DD efforts in their small molecule portfolio.

article thumbnail

A new drug approval for the vanguard of RNA-targeted small molecules

Dark Matter Blog

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.

article thumbnail

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

The Pharma Data

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. About Takeda Pharmaceutical Company Limited. A replay of the call will be available on the Ovid Therapeutics website following the completion of the call and will be archived for 30 days. selective GABA A receptor agonist.

article thumbnail

The Dangers of Mirrored Life

Codon

DNA and RNA molecules are also built from exclusively right-handed nucleic acids. Glucose is a chiral molecule because its structure allows for two distinct configurations, or enantiomers, which cannot be superimposed on each other. The mirrored enzyme seamlessly transcribed 2,900 bases of mirrored DNA into mirrored RNA.

RNA 103
article thumbnail

Biopharma Leaders Unite To Stand With Science

The Pharma Data

Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. About the Janssen Pharmaceutical Companies of. www.jnj.com. www.sec.gov.

Science 52